FibroBiologics stockholders approve capital stock increase and share issuance to YA II PN

FibroBiologics, Inc.

Authorized capital stock increased via amendment to certificate of incorporation effective June 12, 2025.
Stockholders elected Matthew Link and Victoria Niklas, M.D. as Class II directors until 2028.
Ratified WithumSmith+Brown, PC as independent auditor for FY 2025; votes: 53,940,908 for, 73,899 against, 528,109 abstain.
Approved issuance of common stock to YA II PN, LTD., exceeding 7,013,635 shares under Standby Equity Purchase Agreement.
Proxies representing 54,542,916 votes (77.4% of eligible) were present at the annual meeting.

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.